Some may ask why we are growing right now before the

New Post Public Reply Private Reply Replies (1) Message Board
Hate Liars
378
Some may ask why we are growing right now before the anticipated PR of deals and revenues. This is because the CEO of Strikeforce was interviewed on TV on Fox Business News and was also interviewed via radio/internet the day before yesterday again. In both interviews he stated assertively that the large deals that were anticipated to start late last year are just NOW getting implemented with a PR regarding recurring revenues coming in the next 60-90 days. He also stated that the deals are large and with household name companies and that Strikeforce Technologies was finally, after 16 years, becoming profitable. Something he has never stated in the past.

Now, we must state, that there are other catalysts as well that will drive Strikeforce into the future, their new subsidiary company Blocksafe Technologies and their numerous current infringement lawsuits, but these catalysts have NOTHING to do with the PPS rising at this time. It is the anticipated recurring revenues and large deals that are coming that will FINALLY make Strikeforce Technologies profitable that is driving up the PPS. Is it justified? Do folks believe that the CEO of Strikeforce, Mark Kay, is believable about what he has said several times now?

The increasing PPS, volume/buying & accumulating of shares has provided the Market's answer. I personally purchased 2 million shares myself yesterday.

We'll look back in the upcoming years on our time RIGHT NOW, Q1 2018, as the last window of opportunity we had to accumulate shares before Strikeforce Technologies became a typical large cyber defense corporation.

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading